The global Epilepsy Drugs Market is anticipated to rise at a staggering CAGR in the forthcoming period. Epilepsy drugs have pharmacokinetic properties and are administered to children, adults, and adolescents. Carbamazepine is applicable for focal seizures with strong properties of inducing and enables development of milder tolerance level that could be increased weekly.
Epilepsy drugs market is highly driven by rise in cases of stroke, brain tumors, and brain injury. Antiepileptic drugs are prescribed due to the rising demands for treatment for epilepsy. Adoption of novel approach by manufacturers for production of therapeutic drugs also contributes to the market growth in the forecast period.
Download Free Sample Report @ https://www.millioninsights.com/industry-reports/epilepsy-drugs-market/request-sample
Change in lifestyle and increase in geriatric population with unmet medical needs along with rise in awareness is expected to trigger the market growth in the near future. However, rise in demand for generic drugs and availability of cheaper substitutes are likely to hinder the market growth in the forecast period.
On the basis of generation, the epilepsy drugs market is segmented as first generation epileptic drugs, second generation epileptic drugs, and pipeline drugs. Pipeline drugs hold a significant market share in the forecast period due to their enhanced efficiency and efficacy.
Geographical segmentation for epilepsy drugs industry includes North America, South America, Europe, Asia-Pacific, Middle East and Africa. North America is a huge market exhibiting higher potential in terms of diagnosis and treatments coupled with rise in prevalence of epilepsy since it has affected a major population in the United States.
Asia-Pacific regions have also registered a remarkable growth in the forecast period due to high prevalence of epilepsy in several parts of the region. Availability of drugs and treatment through novel mechanisms are some factors driving the market growth for APAC. Latin America is a huge market for epilepsy drugs that encompasses significant healthcare expenditure along with higher prevalence of epileptic cases in the region. The key players in the epilepsy drugs market include Sanofi S.A., UCB Pharma Ltd, Valeant Pharmaceuticals, Pfizer Inc, Johnson & Johnson Co, Abbott Laboratories Inc, Novartis AG, GlaxoSmithKline PLC, CephalonInc, and SunovionPharamceuticals.
Market Segment:
Global Epilepsy Drug market (Revenue, USD Million, 2013 - 2024)
- First generation anti-epileptic drug
- Second generation anti-epileptic drug
- Third generation anti-epileptic drug
Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2013 - 2024)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- India
- China
- Latin America
- Brazil
- MEA
- South Africa
Continued…
San Francisco, 28 May 2020 — “Epilepsy Drugs Market Analysis By Regions (North America, Europe, Asia-Pacific, Latin America and Africa), Product, By Application And Segment Forecasts To 2025” Global Epilepsy Drugs Market is anticipated to rise at a staggering CAGR in the forthcoming period.
Epilepsy drugs have pharmacokinetic properties and are administered to children, adults, and adolescents.
Carbamazepine is applicable for focal seizures with strong properties of inducing and enables development of milder tolerance level that could be increased weekly.
Epilepsy drugs market is highly driven by rise in cases of stroke, brain tumors, and brain injury.
Adoption of novel approach by manufacturers for production of therapeutic drugs also contributes to the market growth in the forecast period.
Pipeline drugs hold a significant market share in the forecast period due to their enhanced efficiency and efficacy.
Global anti-epilepsy drugs market Information, Types of seizures (Generalized seizures and Partial-onset seizures), By Generation (First, second and third) - Forecast to 2022Market HighlightsEpilepsy is a chronic disorder that causes unprovoked and recurrent seizures.
Increasing prevalence of the epilepsy, rising per capita healthcare expenditure and increasing R for the therapeutic procedures of the disease drives the market growth during the forecast period, 2017-2022.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/2345According to the World Health Organization in 2017, approximately 50 million people across the globe have epilepsy, making it one of the most common neurological diseases globally.
International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.
The intense competition prevalent in the market dictates the consolidation among marketers.Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.Pfizer Inc. is one of the major players of the global anti-epilepsy drugs market and is headquartered in the U.S.
Such a significant increase in the global sales, enabled the company to invest a huge percentage of their sales into the research and development.
Celgene has done an agreement with Abbott to develop and commercialize the diagnostic tests.In November 2016, Novartis acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.In August 2017, Sanofi completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, Connecticut in the United States.
